25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CTNM (Contineum Therapeutics, Inc. Class A Common Stock) Stock Analysis
Buy, Hold or Sell?

Let's analyze Contineum Therapeutics, Inc. Class A Common Stock together

I guess you are interested in Contineum Therapeutics, Inc. Class A Common Stock. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Contineum Therapeutics, Inc. Class A Common Stock’s Financial Insights
  • 📈 Technical Analysis (TA) – Contineum Therapeutics, Inc. Class A Common Stock’s Price Targets

I'm going to help you getting a better view of Contineum Therapeutics, Inc. Class A Common Stock. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Contineum Therapeutics, Inc. Class A Common Stock

I send you an email if I find something interesting about Contineum Therapeutics, Inc. Class A Common Stock.

1. Quick Overview

1.1. Quick analysis of Contineum Therapeutics, Inc. Class A Common Stock (30 sec.)










1.2. What can you expect buying and holding a share of Contineum Therapeutics, Inc. Class A Common Stock? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$8.79
Expected worth in 1 year
$20.28
How sure are you?
44.4%

+ What do you gain per year?

Total Gains per Share
$11.49
Return On Investment
288.0%

For what price can you sell your share?

Current Price per Share
$3.99
Expected price per share
$0 - $5.255
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Contineum Therapeutics, Inc. Class A Common Stock (5 min.)




Live pricePrice per Share (EOD)
$3.99

2.2. Growth of Contineum Therapeutics, Inc. Class A Common Stock (5 min.)




Is Contineum Therapeutics, Inc. Class A Common Stock growing?

Current yearPrevious yearGrowGrow %
How rich?$198m-$78.8m$216.4m157.3%

How much money is Contineum Therapeutics, Inc. Class A Common Stock making?

Current yearPrevious yearGrowGrow %
Making money-$10.5m$5.6m-$16.2m-153.8%
Net Profit Margin0.0%20.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Contineum Therapeutics, Inc. Class A Common Stock (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Contineum Therapeutics, Inc. Class A Common Stock?

Welcome investor! Contineum Therapeutics, Inc. Class A Common Stock's management wants to use your money to grow the business. In return you get a share of Contineum Therapeutics, Inc. Class A Common Stock.

First you should know what it really means to hold a share of Contineum Therapeutics, Inc. Class A Common Stock. And how you can make/lose money.

Speculation

The Price per Share of Contineum Therapeutics, Inc. Class A Common Stock is $3.99. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Contineum Therapeutics, Inc. Class A Common Stock.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Contineum Therapeutics, Inc. Class A Common Stock, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $8.79. Based on the TTM, the Book Value Change Per Share is $2.87 per quarter. Based on the YOY, the Book Value Change Per Share is $0.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Contineum Therapeutics, Inc. Class A Common Stock.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.65-16.2%-0.43-10.8%0.225.5%-0.13-3.2%-0.13-3.2%-0.13-3.2%
Usd Book Value Change Per Share0.6215.4%2.8772.0%0.256.3%0.9824.5%0.9824.5%0.9824.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.6215.4%2.8772.0%0.256.3%0.9824.5%0.9824.5%0.9824.5%
Usd Price Per Share14.65-12.85-0.00-5.71-5.71-5.71-
Price to Earnings Ratio-5.67--7.56-0.00--3.36--3.36--3.36-
Price-to-Total Gains Ratio23.77--13.95--13.95--13.95--13.95-
Price to Book Ratio1.67-1.52-0.00-0.68-0.68-0.68-
Price-to-Total Gains Ratio23.77--13.95--13.95--13.95--13.95-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.99
Number of shares250
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share2.870.98
Usd Total Gains Per Share2.870.98
Gains per Quarter (250 shares)718.13244.08
Gains per Year (250 shares)2,872.51976.31
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10287328630976966
2057455736019531942
3086188609029292918
401149011482039053894
501436314355048824870
601723517228058585846
702010820101068346822
802298022974078107798
902585325847087878774
1002872528720097639750

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.08.00.011.1%1.08.00.011.1%1.08.00.011.1%1.08.00.011.1%
Book Value Change Per Share2.02.00.050.0%4.04.01.044.4%4.04.01.044.4%4.04.01.044.4%4.04.01.044.4%
Dividend per Share0.00.04.00.0%0.00.09.00.0%0.00.09.00.0%0.00.09.00.0%0.00.09.00.0%
Total Gains per Share2.02.00.050.0%4.04.01.044.4%4.04.01.044.4%4.04.01.044.4%4.04.01.044.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Contineum Therapeutics, Inc. Class A Common Stock compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.6162.873-79%0.251+145%0.976-37%0.976-37%0.976-37%
Book Value Per Share--8.7875.618+56%-3.089+135%0.712+1134%0.712+1134%0.712+1134%
Current Ratio--20.69333.969-39%10.446+98%20.452+1%20.452+1%20.452+1%
Debt To Asset Ratio--0.0690.431-84%2.161-97%1.468-95%1.468-95%1.468-95%
Debt To Equity Ratio--0.0750.030+149%1.832-96%0.827-91%0.827-91%0.827-91%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--520211052.050629525470.123-17%--629525470.123-17%629525470.123-17%629525470.123-17%
Eps---0.646-0.431-33%0.218-396%-0.128-80%-0.128-80%-0.128-80%
Ev To Ebitda Ratio---8.975-14.931+66%---14.931+66%-14.931+66%-14.931+66%
Free Cash Flow Per Share---0.460-0.338-26%0.181-354%-0.088-81%-0.088-81%-0.088-81%
Free Cash Flow To Equity Per Share---0.4310.722-160%0.728-159%0.624-169%0.624-169%0.624-169%
Gross Profit Margin--1.0001.0030%1.0050%1.0050%1.0050%1.0050%
Market Cap76378176.000-332%330232052.050318922852.593+4%-+100%141743490.041+133%141743490.041+133%141743490.041+133%
Net Profit Margin----0%0.208-100%0.092-100%0.092-100%0.092-100%
Operating Margin----0%0.212-100%0.094-100%0.094-100%0.094-100%
Operating Ratio----0%0.055-100%0.025-100%0.025-100%0.025-100%
Pb Ratio0.454-267%1.6671.523+9%-+100%0.677+146%0.677+146%0.677+146%
Pe Ratio-1.544+73%-5.668-7.558+33%--100%-3.359-41%-3.359-41%-3.359-41%
Price Per Share3.990-267%14.65012.850+14%-+100%5.711+157%5.711+157%5.711+157%
Price To Free Cash Flow Ratio-2.169+73%-7.963-10.254+29%--100%-4.557-43%-4.557-43%-4.557-43%
Price To Total Gains Ratio6.475-267%23.774-13.949+159%---13.949+159%-13.949+159%-13.949+159%
Quick Ratio--38.85959.256-34%19.203+102%36.179+7%36.179+7%36.179+7%
Return On Assets---0.068-0.056-18%0.155-144%0.028-348%0.028-348%0.028-348%
Return On Equity---0.074-0.041-44%0.234-131%0.086-186%0.086-186%0.086-186%
Total Gains Per Share--0.6162.873-79%0.251+145%0.976-37%0.976-37%0.976-37%
Usd Book Value--198066000.000137542000.000+44%-78876000.000+140%15716888.889+1160%15716888.889+1160%15716888.889+1160%
Usd Book Value Change Per Share--0.6162.873-79%0.251+145%0.976-37%0.976-37%0.976-37%
Usd Book Value Per Share--8.7875.618+56%-3.089+135%0.712+1134%0.712+1134%0.712+1134%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--520211052.050629525470.123-17%--629525470.123-17%629525470.123-17%629525470.123-17%
Usd Eps---0.646-0.431-33%0.218-396%-0.128-80%-0.128-80%-0.128-80%
Usd Free Cash Flow---10368000.000-8339750.000-20%4733750.000-319%-2055666.667-80%-2055666.667-80%-2055666.667-80%
Usd Free Cash Flow Per Share---0.460-0.338-26%0.181-354%-0.088-81%-0.088-81%-0.088-81%
Usd Free Cash Flow To Equity Per Share---0.4310.722-160%0.728-159%0.624-169%0.624-169%0.624-169%
Usd Market Cap76378176.000-332%330232052.050318922852.593+4%-+100%141743490.041+133%141743490.041+133%141743490.041+133%
Usd Price Per Share3.990-267%14.65012.850+14%-+100%5.711+157%5.711+157%5.711+157%
Usd Profit---14565000.000-10564500.000-27%5680000.000-356%-3005555.556-79%-3005555.556-79%-3005555.556-79%
Usd Revenue----0%12500000.000-100%5555555.556-100%5555555.556-100%5555555.556-100%
Usd Total Gains Per Share--0.6162.873-79%0.251+145%0.976-37%0.976-37%0.976-37%
 EOD+2 -6MRQTTM+9 -24YOY+17 -163Y+15 -225Y+15 -2210Y+15 -22

3.3 Fundamental Score

Let's check the fundamental score of Contineum Therapeutics, Inc. Class A Common Stock based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.544
Price to Book Ratio (EOD)Between0-10.454
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than138.859
Current Ratio (MRQ)Greater than120.693
Debt to Asset Ratio (MRQ)Less than10.069
Debt to Equity Ratio (MRQ)Less than10.075
Return on Equity (MRQ)Greater than0.15-0.074
Return on Assets (MRQ)Greater than0.05-0.068
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Contineum Therapeutics, Inc. Class A Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose3.810
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2025-04-28 00:54:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Contineum Therapeutics, Inc. Class A Common Stock earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Contineum Therapeutics, Inc. Class A Common Stock to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Contineum Therapeutics, Inc. Class A Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY20.8%-20.8%
TTM-5Y9.2%-9.2%
5Y9.2%10Y9.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--92.5%+92.5%
TTM--182.1%+182.1%
YOY20.8%-197.2%+218.0%
3Y9.2%-242.9%+252.1%
5Y9.2%-348.0%+357.2%
10Y9.2%-488.5%+497.7%
4.3.1.2. Return on Assets

Shows how efficient Contineum Therapeutics, Inc. Class A Common Stock is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Contineum Therapeutics, Inc. Class A Common Stock to the Biotechnology industry mean.
  • -6.8% Return on Assets means that Contineum Therapeutics, Inc. Class A Common Stock generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Contineum Therapeutics, Inc. Class A Common Stock:

  • The MRQ is -6.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.8%TTM-5.6%-1.2%
TTM-5.6%YOY15.5%-21.1%
TTM-5.6%5Y2.8%-8.4%
5Y2.8%10Y2.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.8%-11.3%+4.5%
TTM-5.6%-11.6%+6.0%
YOY15.5%-11.5%+27.0%
3Y2.8%-11.7%+14.5%
5Y2.8%-12.6%+15.4%
10Y2.8%-14.2%+17.0%
4.3.1.3. Return on Equity

Shows how efficient Contineum Therapeutics, Inc. Class A Common Stock is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Contineum Therapeutics, Inc. Class A Common Stock to the Biotechnology industry mean.
  • -7.4% Return on Equity means Contineum Therapeutics, Inc. Class A Common Stock generated $-0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Contineum Therapeutics, Inc. Class A Common Stock:

  • The MRQ is -7.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.4%TTM-4.1%-3.3%
TTM-4.1%YOY23.4%-27.5%
TTM-4.1%5Y8.6%-12.7%
5Y8.6%10Y8.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.4%-15.0%+7.6%
TTM-4.1%-15.1%+11.0%
YOY23.4%-15.1%+38.5%
3Y8.6%-17.6%+26.2%
5Y8.6%-18.1%+26.7%
10Y8.6%-20.1%+28.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Contineum Therapeutics, Inc. Class A Common Stock.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Contineum Therapeutics, Inc. Class A Common Stock is operating .

  • Measures how much profit Contineum Therapeutics, Inc. Class A Common Stock makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Contineum Therapeutics, Inc. Class A Common Stock to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Contineum Therapeutics, Inc. Class A Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY21.2%-21.2%
TTM-5Y9.4%-9.4%
5Y9.4%10Y9.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--184.5%+184.5%
TTM--287.9%+287.9%
YOY21.2%-208.5%+229.7%
3Y9.4%-244.6%+254.0%
5Y9.4%-355.2%+364.6%
10Y9.4%-475.0%+484.4%
4.3.2.2. Operating Ratio

Measures how efficient Contineum Therapeutics, Inc. Class A Common Stock is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Contineum Therapeutics, Inc. Class A Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.055-0.055
TTM-5Y0.025-0.025
5Y0.02510Y0.0250.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.181-2.181
TTM-3.031-3.031
YOY0.0552.985-2.930
3Y0.0253.629-3.604
5Y0.0254.790-4.765
10Y0.0256.545-6.520
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Contineum Therapeutics, Inc. Class A Common Stock.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Contineum Therapeutics, Inc. Class A Common Stock is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 20.69 means the company has $20.69 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Contineum Therapeutics, Inc. Class A Common Stock:

  • The MRQ is 20.693. The company is very able to pay all its short-term debts. +2
  • The TTM is 33.969. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ20.693TTM33.969-13.276
TTM33.969YOY10.446+23.523
TTM33.9695Y20.452+13.517
5Y20.45210Y20.4520.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.6933.588+17.105
TTM33.9693.932+30.037
YOY10.4464.272+6.174
3Y20.4524.797+15.655
5Y20.4525.817+14.635
10Y20.4526.172+14.280
4.4.3.2. Quick Ratio

Measures if Contineum Therapeutics, Inc. Class A Common Stock is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Contineum Therapeutics, Inc. Class A Common Stock to the Biotechnology industry mean.
  • A Quick Ratio of 38.86 means the company can pay off $38.86 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Contineum Therapeutics, Inc. Class A Common Stock:

  • The MRQ is 38.859. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 59.256. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ38.859TTM59.256-20.397
TTM59.256YOY19.203+40.053
TTM59.2565Y36.179+23.077
5Y36.17910Y36.1790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ38.8592.845+36.014
TTM59.2563.420+55.836
YOY19.2034.105+15.098
3Y36.1794.661+31.518
5Y36.1795.882+30.297
10Y36.1796.505+29.674
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Contineum Therapeutics, Inc. Class A Common Stock.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Contineum Therapeutics, Inc. Class A Common Stock assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Contineum Therapeutics, Inc. Class A Common Stock to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.07 means that Contineum Therapeutics, Inc. Class A Common Stock assets are financed with 6.9% credit (debt) and the remaining percentage (100% - 6.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Contineum Therapeutics, Inc. Class A Common Stock:

  • The MRQ is 0.069. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.431. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.069TTM0.431-0.362
TTM0.431YOY2.161-1.729
TTM0.4315Y1.468-1.036
5Y1.46810Y1.4680.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0690.342-0.273
TTM0.4310.342+0.089
YOY2.1610.330+1.831
3Y1.4680.329+1.139
5Y1.4680.359+1.109
10Y1.4680.382+1.086
4.5.4.2. Debt to Equity Ratio

Measures if Contineum Therapeutics, Inc. Class A Common Stock is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Contineum Therapeutics, Inc. Class A Common Stock to the Biotechnology industry mean.
  • A Debt to Equity ratio of 7.5% means that company has $0.07 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Contineum Therapeutics, Inc. Class A Common Stock:

  • The MRQ is 0.075. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.030. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.075TTM0.030+0.045
TTM0.030YOY1.832-1.802
TTM0.0305Y0.827-0.797
5Y0.82710Y0.8270.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0750.409-0.334
TTM0.0300.427-0.397
YOY1.8320.406+1.426
3Y0.8270.436+0.391
5Y0.8270.447+0.380
10Y0.8270.498+0.329
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Contineum Therapeutics, Inc. Class A Common Stock generates.

  • Above 15 is considered overpriced but always compare Contineum Therapeutics, Inc. Class A Common Stock to the Biotechnology industry mean.
  • A PE ratio of -5.67 means the investor is paying $-5.67 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Contineum Therapeutics, Inc. Class A Common Stock:

  • The EOD is -1.544. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.668. Based on the earnings, the company is expensive. -2
  • The TTM is -7.558. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.544MRQ-5.668+4.124
MRQ-5.668TTM-7.558+1.889
TTM-7.558YOY--7.558
TTM-7.5585Y-3.359-4.199
5Y-3.35910Y-3.3590.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.544-1.851+0.307
MRQ-5.668-2.438-3.230
TTM-7.558-3.022-4.536
YOY--3.297+3.297
3Y-3.359-4.006+0.647
5Y-3.359-6.199+2.840
10Y-3.359-6.796+3.437
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Contineum Therapeutics, Inc. Class A Common Stock:

  • The EOD is -2.169. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.963. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.254. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.169MRQ-7.963+5.794
MRQ-7.963TTM-10.254+2.291
TTM-10.254YOY--10.254
TTM-10.2545Y-4.557-5.697
5Y-4.55710Y-4.5570.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.169-2.532+0.363
MRQ-7.963-3.298-4.665
TTM-10.254-3.938-6.316
YOY--4.309+4.309
3Y-4.557-5.461+0.904
5Y-4.557-8.408+3.851
10Y-4.557-9.443+4.886
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Contineum Therapeutics, Inc. Class A Common Stock is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.67 means the investor is paying $1.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Contineum Therapeutics, Inc. Class A Common Stock:

  • The EOD is 0.454. Based on the equity, the company is cheap. +2
  • The MRQ is 1.667. Based on the equity, the company is underpriced. +1
  • The TTM is 1.523. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.454MRQ1.667-1.213
MRQ1.667TTM1.523+0.144
TTM1.523YOY-+1.523
TTM1.5235Y0.677+0.846
5Y0.67710Y0.6770.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4541.813-1.359
MRQ1.6672.184-0.517
TTM1.5232.403-0.880
YOY-2.480-2.480
3Y0.6772.766-2.089
5Y0.6773.735-3.058
10Y0.6774.330-3.653
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-12-312024-03-312024-06-302024-09-302024-12-31
Operating Income  -9,676-254-9,930-1,014-10,944-2,030-12,97497,71584,741
Total Operating Expenses  9,6392309,8691,01510,8842,09012,974-97,715-84,741
Total Other Income Expense Net 1,746-2331,5134221,9357722,707-102,013-99,306



6.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets212,847
Total Liabilities14,781
Total Stockholder Equity198,066
 As reported
Total Liabilities 14,781
Total Stockholder Equity+ 198,066
Total Assets = 212,847

Assets

Total Assets212,847
Total Current Assets206,388
Long-term Assets6,459
Total Current Assets
Cash And Cash Equivalents 21,943
Short-term Investments 182,817
Other Current Assets 1,628
Total Current Assets  (as reported)206,388
Total Current Assets  (calculated)206,388
+/-0
Long-term Assets
Property Plant Equipment 6,456
Long-term Assets Other 3
Long-term Assets  (as reported)6,459
Long-term Assets  (calculated)6,459
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities9,974
Long-term Liabilities4,807
Total Stockholder Equity198,066
Total Current Liabilities
Short-term Debt 1,452
Accounts payable 1,811
Other Current Liabilities 6,711
Total Current Liabilities  (as reported)9,974
Total Current Liabilities  (calculated)9,974
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt4,807
Long-term Liabilities  (as reported)4,807
Long-term Liabilities  (calculated)4,807
+/-0
Total Stockholder Equity
Common Stock26
Retained Earnings -117,402
Accumulated Other Comprehensive Income 71
Other Stockholders Equity 315,371
Total Stockholder Equity (as reported)198,066
Total Stockholder Equity (calculated)198,066
+/-0
Other
Capital Stock26
Cash and Short Term Investments 204,760
Common Stock Shares Outstanding 22,541
Liabilities and Stockholders Equity 212,847
Net Debt -15,684
Net Invested Capital 198,066
Net Working Capital 196,414
Property Plant and Equipment Gross 8,173
Short Long Term Debt Total 6,259



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
> Total Assets 
50,636
0
0
139,045
130,386
123,564
221,355
216,034
212,847
212,847216,034221,355123,564130,386139,0450050,636
   > Total Current Assets 
48,392
47,239
0
137,529
127,706
119,711
220,320
215,143
206,388
206,388215,143220,320119,711127,706137,529047,23948,392
       Cash And Cash Equivalents 
5,569
-47,239
0
17,521
15,526
16,264
77,230
40,891
21,943
21,94340,89177,23016,26415,52617,5210-47,2395,569
       Short-term Investments 
41,670
94,478
0
117,604
109,664
101,643
141,423
173,020
182,817
182,817173,020141,423101,643109,664117,604094,47841,670
       Other Current Assets 
1,153
0
0
2,404
2,516
1,804
1,667
1,232
1,628
1,6281,2321,6671,8042,5162,404001,153
   > Long-term Assets 
2,244
-47,239
0
1,516
2,680
3,853
1,035
891
6,459
6,4598911,0353,8532,6801,5160-47,2392,244
       Property Plant Equipment 
2,115
0
0
1,361
1,397
1,230
1,032
888
6,456
6,4568881,0321,2301,3971,361002,115
       Long-term Assets Other 
129
-47,239
0
155
1,283
2,623
3
3
3
3332,6231,2831550-47,239129
> Total Liabilities 
143,848
0
0
200,189
198,322
199,193
3,852
5,806
14,781
14,7815,8063,852199,193198,322200,18900143,848
   > Total Current Liabilities 
7,550
0
0
7,436
5,484
6,234
3,739
5,806
9,974
9,9745,8063,7396,2345,4847,436007,550
       Short-term Debt 
5,058
0
0
1,121
464
948
968
611
1,452
1,4526119689484641,121005,058
       Short Long Term Debt 
3,948
0
0
0
0
0
0
0
0
000000003,948
       Accounts payable 
430
0
0
1,054
635
570
734
1,397
1,811
1,8111,3977345706351,05400430
       Other Current Liabilities 
2,062
0
0
4,585
4,385
4,716
2,037
3,798
6,711
6,7113,7982,0374,7164,3854,585002,062
   > Long-term Liabilities 
136,298
0
0
192,753
192,838
192,959
113
0
4,807
4,8070113192,959192,838192,75300136,298
       Capital Lease Obligations 
1,901
0
0
1,121
572
585
597
611
6,259
6,2596115975855721,121001,901
       Long-term Liabilities Other 
3,025
0
0
133
110
228
0
0
0
000228110133003,025
> Total Stockholder Equity
-93,212
39,270
0
-61,144
-67,936
-75,629
217,503
210,228
198,066
198,066210,228217,503-75,629-67,936-61,144039,270-93,212
   Common Stock
12
0
0
13
13
2
26
26
26
262626213130012
   Retained Earnings -117,402-102,837-92,570-83,561-75,144-67,37500-97,864
   Accumulated Other Comprehensive Income 
-76
-93,212
0
-89
108
-58
-127
561
71
71561-127-58108-890-93,212-76
   Capital Surplus 000000000
   Treasury Stock000000000
   Other Stockholders Equity 
4,726
0
0
6,307
7,098
-192,620
310,174
312,478
315,371
315,371312,478310,174-192,6207,0986,307004,726



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in USD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-50,894
Operating Income-50,894-50,894
 
Operating Expense (+$)
Research Development38,422
Selling General Administrative12,472
Selling And Marketing Expenses0
Operating Expense50,89450,894
 
Net Interest Income (+$)
Interest Income8,905
Interest Expense-0
Other Finance Cost-0
Net Interest Income8,905
 
Pretax Income (+$)
Operating Income-50,894
Net Interest Income8,905
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-42,258-59,530
EBIT - interestExpense = 0
-42,258
-42,258
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-42,258
Earnings Before Interest and Taxes (EBITDA)-50,894
 
After tax Income (+$)
Income Before Tax-42,258
Tax Provision-0
Net Income From Continuing Ops-42,258-42,258
Net Income-42,258
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net8,636-8,905
 

Technical Analysis of Contineum Therapeutics, Inc. Class A Common Stock
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Contineum Therapeutics, Inc. Class A Common Stock. The general trend of Contineum Therapeutics, Inc. Class A Common Stock is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Contineum Therapeutics, Inc. Class A Common Stock's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Contineum Therapeutics, Inc. Class A Common Stock Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Contineum Therapeutics, Inc. Class A Common Stock.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 3.91 < 3.91 < 5.255.

The bearish price targets are: .

Know someone who trades $CTNM? Share this with them.👇

Contineum Therapeutics, Inc. Class A Common Stock Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Contineum Therapeutics, Inc. Class A Common Stock. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Contineum Therapeutics, Inc. Class A Common Stock Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Contineum Therapeutics, Inc. Class A Common Stock.

Contineum Therapeutics, Inc. Class A Common Stock Daily Moving Average Convergence/Divergence (MACD) ChartContineum Therapeutics, Inc. Class A Common Stock Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Contineum Therapeutics, Inc. Class A Common Stock. The current adx is .

Contineum Therapeutics, Inc. Class A Common Stock Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Contineum Therapeutics, Inc. Class A Common Stock.

Contineum Therapeutics, Inc. Class A Common Stock Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Contineum Therapeutics, Inc. Class A Common Stock.

Contineum Therapeutics, Inc. Class A Common Stock Daily Relative Strength Index (RSI) ChartContineum Therapeutics, Inc. Class A Common Stock Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Contineum Therapeutics, Inc. Class A Common Stock.

Contineum Therapeutics, Inc. Class A Common Stock Daily Stochastic Oscillator ChartContineum Therapeutics, Inc. Class A Common Stock Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Contineum Therapeutics, Inc. Class A Common Stock.

Contineum Therapeutics, Inc. Class A Common Stock Daily Commodity Channel Index (CCI) ChartContineum Therapeutics, Inc. Class A Common Stock Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Contineum Therapeutics, Inc. Class A Common Stock.

Contineum Therapeutics, Inc. Class A Common Stock Daily Chande Momentum Oscillator (CMO) ChartContineum Therapeutics, Inc. Class A Common Stock Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Contineum Therapeutics, Inc. Class A Common Stock.

Contineum Therapeutics, Inc. Class A Common Stock Daily Williams %R ChartContineum Therapeutics, Inc. Class A Common Stock Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Contineum Therapeutics, Inc. Class A Common Stock.

Contineum Therapeutics, Inc. Class A Common Stock Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Contineum Therapeutics, Inc. Class A Common Stock.

Contineum Therapeutics, Inc. Class A Common Stock Daily Average True Range (ATR) ChartContineum Therapeutics, Inc. Class A Common Stock Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Contineum Therapeutics, Inc. Class A Common Stock.

Contineum Therapeutics, Inc. Class A Common Stock Daily On-Balance Volume (OBV) ChartContineum Therapeutics, Inc. Class A Common Stock Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Contineum Therapeutics, Inc. Class A Common Stock.

Contineum Therapeutics, Inc. Class A Common Stock Daily Money Flow Index (MFI) ChartContineum Therapeutics, Inc. Class A Common Stock Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Contineum Therapeutics, Inc. Class A Common Stock.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-01-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-14BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-16STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-01-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-04-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-16MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-04-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Contineum Therapeutics, Inc. Class A Common Stock Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Contineum Therapeutics, Inc. Class A Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose3.810
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Contineum Therapeutics, Inc. Class A Common Stock with someone you think should read this too:
  • Are you bullish or bearish on Contineum Therapeutics, Inc. Class A Common Stock? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Contineum Therapeutics, Inc. Class A Common Stock? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Contineum Therapeutics, Inc. Class A Common Stock

I send you an email if I find something interesting about Contineum Therapeutics, Inc. Class A Common Stock.


Comments

How you think about this?

Leave a comment

Stay informed about Contineum Therapeutics, Inc. Class A Common Stock.

Receive notifications about Contineum Therapeutics, Inc. Class A Common Stock in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.